A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Advanced relapsed or refractory ovarian cancer
Advanced relapsed or refractory endometrial cancer
Advanced relapsed or refractory germ cell tumours
Спонсор: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Налично на:
БГ
Обобщение
Trial status: Authorised
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 65 participants
БГ
EN